Manulife Singapore Partners with Guardant Health to Bring Award-Winning Multi-Cancer Screening to Customers

SINGAPORE - Manulife Singapore today announced the availability of the Shield^TM multi-cancer detection (MCD) laboratory developed test (LDT) in Singapore from May 2026, as part of its existing partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. This makes Manulife the first insurer in Singapore to offer eligible customers the Shield^TM MCD test, which won the Oncology Product Innovation of the Year at the recent Healthcare Asia Medtech Awards. This exclusive Asia partnership spanning Hong Kong, the Philippines and Singapore reflects Manulife's commitment to customers' wellbeing and helping them live well for longer.

The collaboration builds on the companies' existing relationship that offers customers in Singapore access to the Guardant360® Liquid test for advanced solid tumours. Through this expanded partnership and introduction of the Shield™ MCD test, customers will have access to an innovative and differentiated solution that address real, unmet health needs. This underscores Manulife Singapore's commitment to longevity and providing its customers with a well-being ecosystem that supports them across their health journeys.

"As people live longer, the real question is how well we live those years," said Benoit Meslet, President and CEO, Manulife Singapore. "Our role is to help customers take charge of their health and finances with confidence. By giving them early visibility into their health, we are helping them make better decisions today, so they can live well for years to come."

Singapore continues to move towards preventive and personalised care as the country responds to the growing health needs of a super-aged society. Cancer remains the leading cause of death in Singapore, accounting for 26.5% of all deaths in 2024 and underscoring the importance of early detection. This reflects findings from the Manulife Asia Care Survey 2025, which show that 53% of Singapore consumers believe cancer to be the most difficult illness to prevent. Access to the Shield™ MCD test, therefore, enables proactive health management.

The Shield™ MCD test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).* With just a blood draw, it screens for 10 of the most common cancers, many of which have high mortality rates in Singapore.

"We are excited to further our partnership with Manulife by introducing the Shield™ MCD test to their customers in Singapore," said Simranjit Singh, CEO of Guardant Health AMEA. "By reducing barriers to cancer screening with just a blood draw, Shield™ MCD has the potential to address the growing burden of cancer in Singapore. This collaboration reflects our shared commitment to providing access to innovative health solutions, and we look forward to the positive impact we can make together."

"Singapore consumers value the quality of years lived as they seek to age with dignity and independence - and preventive care plays a critical role in making that possible," said Michelle Fang, Chief Marketing Officer, Manulife Singapore. "As the only insurer in Singapore to offer the Shield™ MCD test, we reinforce our promise to provide customers with trusted, innovative health solutions that support their longevity. Paired with our wealth planning expertise, this enables them to plan for their future confidently."

Manulife supports customers' health and wealth planning through solutions that meet diverse needs across every stage of life. As part of this commitment, Manulife commissions the annual Asia Care Survey to better understand public perceptions and customer needs, and champions multiple initiatives in the longevity space including its inaugural Longevity Symposium and flagship lifestyle programme ManulifeMOVE. This partnership with Guardant Health strengthens Manulife Singapore's overall longevity offerings and leadership.

These efforts also align with the Manulife Longevity Institute, a global research, thought leadership, innovation, advocacy, and community investment platform that aims to drive action to help people live longer, healthier, more financially secure lives.

*The FDA Breakthrough Device designation referenced eight cancer types-bladder, colorectal, oesophageal, gastric, liver, lung, ovarian, and pancreatic cancer¹

- End -